Monday, October 5, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

Montana’s plan to become an experimental medical hub just pushed forward

View original at technologyreview.com
MIT Technology Review - Ai Research Title: Montana’s plan to become an experimental medical hub just pushed forward Date: 2026-07-30 17:10 Source: https://www.technologyreview.com/2026/07/30/1140942/montana-experimental-medical-hub-pushed-forward-right-to-try/ <div></div> <p>As of this week in Montana, any biotech comp…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The rules took a very long time and became effective from Saturday, July 25.

    60% confidence

  • His vision for right-to-try was to focus more on preventative medicine rather than just treating diseases once they show up.

    60% confidence

  • Justice saw an opportunity to help build a safe, transparent, scientifically rigorous process for implementing Montana's right-to-try legislation, especially for longevity medicines.

    60% confidence

  • Oncology and neurodegenerative disease treatments are compatible with Infinita's longevity mission; the goal is not solely to convince everyone to support radical life extension.

    60% confidence

  • Concerned about potential harm from selling unproven treatments without FDA oversight.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com